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Background: Vancomycin variable enterococci (VVE) are van-positive isolates with a susceptible phenotype that
can convert to a resistant phenotype during vancomycin selection.
Objectives: To describe a vancomycin-susceptible vanA-PCR positive ST203 VVE Enterococcus faecium isolate
(VVESwe-S) from a liver transplantation patient in Sweden which reverted to resistant (VVESwe-R) during in vitro
vancomycin exposure.
Methods: WGS analysis revealed the genetic differences between the isolates. Expression of the van-operon
was investigated by qPCR. Fitness and stability of the revertant were investigated by growth measurements,
competition and serial transfer.
Results: The VVESwe-R isolate gained high-level vancomycin (MIC >256 mg/L) and teicoplanin resistance
(MIC = 8 mg/L). VVESwe-S has a 50-truncated vanR activator sequence and the VVESwe-R has in addition acquired
a 44 bp deletion upstream of vanHAX in a region containing alternative putative constitutive promoters. In
VVESwe-R the vanHAX-operon is constitutively expressed at a level comparable to the non-induced prototype
E. faecium BM4147 strain. The vanHAX operon of VVESwe is located on an Inc18-like plasmid, which has a
3–4-fold higher copy number in VVESwe-R compared with VVESwe-S. Resistance has a low fitness cost and the
vancomycin MIC of VVESwe-R decreased during in vitro serial culture without selection. The reduction in MIC was
associated with a decreased vanA-plasmid copy number.
Conclusions: Our data support a mechanism by which vancomycin-susceptible VVE strains may revert to a
resistant phenotype through the use of an alternative, constitutive, vanR-activator-independent promoter and
a vanA-plasmid copy number increase.
Introduction
Enterococcus faecium is an important opportunistic pathogen
causing severe MDR infections in hospitalized patients. The in-
crease in VRE causes concerns due to severely limited treatment
options. Vancomycin resistance occurs by the acquisition of one of
several van-gene clusters—vanA, B, C, D, E, G, L, M, and N—of which
vanA and vanB are the most significant clinically.1
Vancomycin-variable enterococci (VVE) is a term used for VRE
where expression of the van genes is phenotypically silenced by
genetic rearrangements, which may be reversed under vanco-
mycin selection.2,3 A complex of seven genes (vanRSHAXYZ)
support the expression of the prototype VanA-type high-level
vancomycin and teicoplanin resistance. Upon exposure to glyco-
peptides the two-component regulators, sensor VanS and
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activator VanR, up-regulate the expression of the enzymes
(VanHAXY) involved in changing the peptidoglycan sidechain ter-
minus from D-Ala-D-Ala to D-Ala-D-Lac. However, only expression of
vanHAX is essential in gaining resistance in strains with a functional
host D-alanine:D-alanine ligase (Ddl).4 In 2009, a Canadian ST18
VVE. faecium was able to convert to a resistant phenotype by the
introduction of IS elements providing novel promoters for constitu-
tive expression of vanHAX and deletions in the promoter region.5,6
By 2015–16, a regional spread of VVE in the Ontario region had
occurred and 47% of the vanA-positive isolates were VVE.7 In
2016, a Danish ST1421 VVE. faecium strain with a 252 bp vanX-
truncation was described. The resistant phenotype was associated
with an increased vanA-plasmid copy number or by disruption of
the host ddl ligase gene.8 By 2019 this clone had spread from the
capital region to all five Danish regions, and the Faroe Islands.9
Early identification of VVEs and their reversion mechanism is
important for therapeutic and infection control measures.
We have previously described a VVE. faecium ST203 outbreak
strain in Norway, where excision of a vanA-operon-inserted ISL3
restored the resistant phenotype.3 The occurrence of VVE will likely
increase corresponding to the increase in VanA-type VRE as the
vanA-gene cluster will be affected by random genetic alterations.
In this study, we show yet another different variant of variable
resistance in a Swedish VVE strain.
Materials and methods
Isolation of VVE
The susceptible parental faecal VVE strain (VVESwe-S) was isolated from
a liver-transplanted patient at Halmstad Hospital, Sweden after faecal
VRE-screening, but the patient never had an E. faecium infection. The VRE-
screening was performed by enrichment in Bile aesculin azide (BEA) broth
supplemented with aztreonam (60 mg/L) and vancomycin (4 mg/L) at
36C for 20–24 h and subsequent vanA/B PCR using Rotor-Gene and
TaqMan probes.10
Vancomycin resistance phenotype reversion and
frequency
Conversion to vancomycin resistance was initiated as described previously3
by incubating a single susceptible VVE colony in 5 mL of Brain Heart Infusion
(BHI) broth (Oxoid) overnight, followed by a 1:100 dilution into 5 mL of BHI
broth containing 2 or 8 mg/L vancomycin.
Resistance reversion frequency determination was based on Sivertsen
et al.3 Ten-fold serial dilution samples of an overnight VVESwe-S strain BHI-
broth culture in biological triplicates and technical triplicates were plated on
BHI agar with and without 6 mg/L vancomycin. The plates were incubated
at 35C and cfu counted after 24 h for plates without vancomycin and after
48 h and 72 h for plates with vancomycin. Vancomycin-resistant revertant
(VVESwe-R) colonies from vancomycin-containing plates were verified by
MALDI-TOF (Bruker), antimicrobial susceptibility testing (AST), and Sanger
sequencing of the vanSH PCR product using primers as described before11
and BigDye 3.1 technology (Applied Biosystems). AST was performed with
vancomycin MIC test strips (Liofilchem) and/or Sensititre EUENCF plate
(Thermo Fisher Scientific) according to the manufacturers’ instructions
with ATCC 29212 as control. JumpStart REDTaq ReadyMix (Merck KGaA)
was used for PCRs. DNA extractions for PCRs were performed using the
NucliSens EasyMAG instrument and reagents (BioMeriéux) according to
the manufacturer’s instructions.
WGS and bioinformatics
Bacterial genomic DNA was isolated with the Qiagen MagAttract HMW DNA
isolation kit (Qiagen) and sequenced by MiSeq using Nextera library con-
struction on 250 bp paired-end runs or by NextSeq500 using the Nextera XT
DNA library preparation kit and the Mid Output 300 cycles cell according to
standard protocols (Illumina). Sequence reads were trimmed using
Trimmomatic v.0.36,12 assembled with Spades v.3.9.0,13 and annotated
with Prokka v.1.11.14 MLST profiles were determined using MLST software15
and core genome (cg)MLST cluster types (CTs) were determined using
SeqSphere!.16
In order to confirm the location of the vanA-gene cluster, the genomes
were closed by nanopore sequencing technology. Nanopore reads were
error-corrected and assembled along with Illumina reads by the hybrid
assembler Unicycler v0.4.7.17 Resistance genes and the replicon type of
van-operon-containing plasmid sequences were identified by scanning the
genomes in Abricate v.8.5 using the NCBI resistance database and
PlasmidFinder database, respectively. Illumina reads were mapped on the
nanopore assemblies using bwa-mem.18 Genome coverage was calculated
by bedtools genomcov option,19 which permitted quantifiable coverage
ratios between the chromosome and the vanA-containing plasmid.
VVESwe-S and VVESwe-R sequences were compared with MUMmer v3.2320
and the SNPs were called using GATK. Genome syntenies of the VVESwe-S
and VVESwe-R genomes and between the VVESwe-S/-R vanA gene cluster
and prototypic Tn1546 (GenBank Acc. No. M97297) were visualized with
ACT,21 and alignment figures were produced with EasyFig v.2.2.2.22 Sanger
sequencing of the vanSH region was performed on the prototypic
Tn1546 as described above to confirm that the sequence has not changed
in reference strain BM4147.
Promoters were predicted in the intergenic region between vanS and
vanH using Softberry.23
Accession numbers
The sequences have been posted to NCBI and can be found under the
BioProject number PRJNA551094 (CP041261-8 and CP041270-8).
Reverse transcription-quantitative PCR (RT-qPCR) on
cDNA and qPCR on gDNA
Quantification of mRNA levels of vanRS and vanHAX was done as described
previously. Primer sequences for qPCR were also described previously.3
For quantification of gDNA levels of vanRS and vanHAX, DNA was
extracted from VVESwe-S, VVESwe-R and BM4147 grown to mid-log-phase
in BHI broth without and with 8 mg/L vancomycin, using the GenElute
Bacterial Genomic DNA Kit (Sigma Aldrich). qPCR was performed using
probes with 50FAM and a 30BHQ-1 quencher (Eurogentec), qPCR Master Mix
Plus Low ROX (Eurogentec) and run on a 7300 Fast Real-Time PCR System
(Applied Biosystems). Cycle threshold (Ct) values were normalized to the
housekeeping gene gdh and DCt was calculated as DCtvanRS = CtvanRS#Ctgdh
and DCtvanHAX = CtvanHAX#Ctgdh. The plasmid copy number was calculated
as 2DCt(vanHAX) since only one copy of gdh is found in all strains, and vanHAX
only localizes to the plasmid of interest (based on Lee et al.24).
Statistical data analysis of qPCR data was performed in GraphPad Prism
7 using an unpaired two-tailed t-test.
Fitness measurements
The relative fitness was assessed through growth rate measurements and
head-to-head competition as described previously.25
Overnight cultures were diluted 1:100 in BHI and growth was measured
in an Epoch 2 Spectrophotometer with Gen5 Software (BioTek Instruments
Inc.) at 37C, shaking at 425 rpm, with OD600 measurement every tenth mi-
nute for 24 h. Growth rates were calculated in the logarithmic growth phase
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comparing the growth rates of VVESwe-S and VVESwe-R using the equation
w = GrowthRateVVESwe-R/GrowthRateVVESwe-S.
For pairwise competition, overnight cultures of VVESwe-S and VVESwe-R
were OD-adjusted (OD600), mixed at a ratio of 1:1 and diluted 1:100 in 5 mL
BHI and incubated for 24 h at 37C with shaking. The initial and final cfu
counts of the competitors were determined on BHI agar without and with
8 mg/L vancomycin. The relative fitness w of the revertant VVESwe-R was
estimated as a ratio of ln(cfu t24/cfu t0) of the revertant to the susceptible
VVESwe-S using the equation w = ln(cfuVVESwe-R t24/cfuVVESwe-R t0)/
ln(cfuVVESwe-S t24/cfuVVESwe-S t0).
27
Statistical data analysis for fitness cost experiments was performed in
GraphPad Prism 7 using an unpaired two-tailed t-test to calculate whether
the value significantly differs from 1.
Resistance stability in VVESwe-R
The revertant was cultured continuously in absence of antibiotic with serial
transfer every 24 h in biological triplicates (30lL inoculated into 3 mL BHI).
Colonies were counted on BHI plates with and without 8 mg/L vancomycin
and the ratio of total cfu to resistant cfu was determined. Colonies were
counted after 24 h and re-checked after 48 h, since the colonies were grow-
ing slowly on the selective plates. One hundred colonies were exposed to
differential plating on BHI plates without and with 8 mg/L vancomycin.
Ten colonies were selected for qPCR analysis to determine vanA-plas-
mid copy, subjected to Sanger sequencing of the vanSH PCR product
as described above and vancomycin MIC test strip (MTS-Liofilchem) with
E. faecalis ATCC 29212 and E. faecium BM4147 as control strains.
Results and discussion
VVESwe resistance phenotype reversion and frequency
The original VVE faecal sample gave a positive vanA-PCR result
from the BEA broth culture which supported growth of single colo-
nies of enterococci on chromogenic and blood agar. Disc diffusion
showed an inhibition zone diameter of 15 mm with a sharp edge
and Etest gradient strips a vancomycin MIC of 2 mg/L. The isolate
was named VVESwe-S. In broth microdilution VVESwe-S expressed
susceptibility to vancomycin (MIC 1 mg/L) and teicoplanin (MIC
<0.5 mg/L) (Tables S1 and S2, available as Supplementary data at
JAC Online).
The VVESwe-S strain reverted to a vancomycin-resistant
phenotype (VVESwe-R) during exposure to vancomycin 6 mg/L or
8 mg/L for 48–72 h. VVESwe-R had gained high-level vancomycin
resistance (MIC >256 mg/L) and teicoplanin resistance (MIC
8 mg/L) (Table S2). The frequency of vancomycin resistance rever-
sion was 2%10#8 resistant colonies per parent cell in vitro after
48 h and 5%10#8 after 72 h. A similar reversion frequency
(3%10#8 after 24 h, 7%10#8 after 48 h) was also detected for the
previously described VVE. faecium ST203 outbreak strain from
Norway, although the reversion mechanism was different.3 A bac-
terial load of above 108 could be reached in certain infection sites
(e.g. infected peritoneal fluids) in a patient28 and thus reversion is
clinically relevant and may occur during vancomycin treatment as
previously observed for other VVE strains.2,3 The VVE isolates
reverted at a frequency that is too low and over a time that is too
long to be detected by standard antimicrobial susceptibility testing
methods, which explains why VVE resistant revertants are difficult
to detect by standard AST methods using a much lower inoculum
(105 bacteria) and reading after 24 h.
Genetic differences between VVESwe-S and VVESwe-R
VVESwe belongs to ST203/CT20 and is unrelated to any global or
local surveillance isolates or the Norwegian ST203/CT465 VVE.3
Early detection of the VVESwe by PCR may have hindered the
spread of this clone before it became prevalent. However, vanA-
positive ST203/CT20 strains were prevalent in Germany among
VRE blood culture isolates (2015–18), but expressed a normal
VanA phenotype (G. Werner, personal communication).
High-quality assemblies were achieved for VVESwe-S and
VVESwe-R genomes with pertinent genome size, GC content, and
coverage of 305% and 252%, respectively. The genomes of the
parental VVESwe-S and the resistant revertant VVESwe-R were
compared and aligned with the prototypical vanA cluster of
BM4147. Both VVESwe-S and VVESwe-R have a 50-truncated vanR
activator gene (Figure 1). The difference between the VVESwe-S
and VVESwe-R strain was a 44 bp deletion covering the inducible
vanHAX promoter region in the resistant strain. Alternative
promoters in the vanHAX promoter region were predicted in sil-
ico (P1 to P5 in Figure 1), but only promoters P1 to P3 changed
their proximity to vanH, thus we predict these promoters to be
responsible for the phenotypic reversion. The additional alter-
native promoters were also found in the prototypical vanA clus-
ter of BM4147 (Figure S1). Promoter prediction solely in silico is a
limitation of this study. However, we were unable to perform
an experimental approach giving high enough resolution to
distinguish putative promoters at the single nucleotide level,
which would be required since the predicted promoters are
overlapping.
The deletion occurred in a region with an IR and a DR and pre-
cisely removes one of the DR sequences as well as the nucleotides
between the DR, which suggests that the deletion occurs by illegit-
imate recombination.29 Genome comparisons and read mapping
with subsequent SNP and variation calling revealed no other
obvious relevant genomic alterations that could be linked to the
phenotypic differences between these isogenic strains, as shown
in Table S3. The whole genome sequence of an additional inde-
pendent revertant VVESwe-R (VVESwe-R2), was also compared
with VVESwe-S and the same 44 bp deletion in the vanHAX pro-
moter region was found (Table S3). Additionally, Sanger
sequencing of the vanSH PCR product of two additional inde-
pendent revertants showed the sequence to be identical to that
in VVESwe-R.
To elucidate the observed difference in vancomycin susceptibil-
ity, we explored the localization and expression of vanHAX in the
VVESwe-R isolate compared with VVESwe-S.
The vanA cluster in VVESwe is located on a plasmid
Genome sequence analysis revealed that the vanA cluster of
VVESwe is located on a 35 kb non-conjugative plasmid (GenBank
Acc. No. CP041279) with a rep previously described as a CDS1 puta-
tive replicon of the plasmid pRE25 belonging to Inc18 theta repli-
cating plasmids of rep class 2.30 In other VVEs the vanA gene
cluster localized on a transferable plasmid, which thus has
a potential to spread vancomycin resistance.3,6,8 However, we
were unable to show transfer of the vanA VVESwe-R in mating
experiments.
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The vanHAX-operon was constitutively expressed in
VVESwe-R
We examined the functionality of the alternative promoter in ab-
sence of the inducible promoter (Figure 1) by RT-qPCR on BM4147,
VVESwe-S and VVESwe-R.
First, the transcription profile of the VanA-prototype strain
BM4147 was analysed. Sanger sequencing of the vanSH PCR prod-
uct confirmed that no genetic changes had occurred in Tn1546 of
BM4147 compared with the reference sequence (GenBank Acc.
No. M97297). Without vancomycin induction, BM4147 expressed
vanRS and vanHAX (Figure 2a), in line with early studies at the pro-
tein level.31,32 This observation was also confirmed in MH broth,
the standard medium for MIC testing (Figure S2). We therefore
assume that in the absence of vancomycin induction, the above-
described alternative constitutive promoters (Figure 1 and Figure
S1) may be used for expression of vanHAX in BM4147, or low-level
activation of the prototype promoter occurs.
Vancomycin exposure significantly increased the expression
of both vanRS and vanHAX in BM4147, in line with the observed
requirement of an intact vanRS for vancomycin induction of
vanHAX (Figure 2a).32–34 The presence of vancomycin triggers
phosphorylation of VanS, phospho-VanS then phosphorylates
the transcriptional activator VanR and Phospho-VanR induces tran-
scription of the vanHAX operon.35
Figure 1. Comparison of the van cluster of VVESwe with the prototype. (Top) Pairwise alignment starting with the start codon up to bp 113 of the
vanR gene of Tn1546 of BM4147 and the 50-truncated vanR of VVESwe. Asterisks represent identity. (Middle) Pairwise alignment of the vanA cluster of
Tn1546 of BM4147 and VVESwe-S. Both VVESwe isolates lack a functional vanR activator gene (light orange box). (Bottom) Pairwise alignment of the
vanSH intergenic region of VVESwe-S and VVESwe-R. VVESwe-S and VVESwe-R comparisons revealed a 44 bp deletion in VVESwe-R, which is con-
nected to direct repeat (DR) and inverted repeat (IR) sequences covering the inducible promoter region. Alternative promoters in VVESwe are marked
with hexagons and numbered P1 to P5. Activator binding sites are indicated as boxes (VanR-P, VanR-phosphate binding site; RBS, ribosomal binding
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The van-operon is considered as a textbook example of indu-
cible resistance to glycopeptide antibiotics. Former studies
observed that the regulatory expression of the vanHAX-operon is
not tight, since VanA was detected in BM4147 membrane extracts
even in the absence of vancomycin induction.31 Our data are con-
sistent with previous studies, supporting the notion of an inducible
prototypic vanA operon of Tn1546 and constitutive low-level
expression of vanHAX in the absence of vancomycin induction.
The transcription profile of VVESwe showed very low expression
of vanRS in both VVESwe-S and VVESwe-R, confirming non-
functionality of vanRS in VVESwe, as predicted by sequence ana-
lysis. VVESwe-S does not express vanHAX, whereas VVESwe-R
expresses vanHAX. The vanHAX-transcription level of VVESwe-R
was similar with and without vancomycin exposure and compar-
able to the non-induced prototype BM4147-level (Figure 2a),
supporting the notion of an alternative constitutive promoter.
Constitutive expression of vanHAX has been described in Canadian
VVE-R strains, but was due to a different set of mutations in the
promoter region.5,6
Furthermore, the copy number of vanHAX at the gDNA level
was measured in BM4147, VVESwe-S and VVESwe-R, in BHI both
with and without vancomycin. Vancomycin exposure did not sig-
nificantly alter the copy number of vanHAX in any strains.
However, VVESwe-R harboured a higher copy number of the
vanHAX-operon (16 ± 3), compared with both BM4147 (6 ± 1) and
VVESwe-S (5 ± 1) (Figure 2b). A higher vanA-plasmid copy number
may support higher expression levels of vanHAX from an alterna-
tive constitutive promoter, and thus in the absence of a functional
vanRS may be responsible for the resistant phenotype. Moreover,
both Illumina and Nanopore WGS analyses confirmed the plasmid
copy number of the vanA-plasmids in VVESwe-R (n = 14) and
VVESwe-S (n = 2). Similarly, vanA-plasmid copy number was
described to confer reversion in an ST1421 strain.8 Recently,
increased vanM gene cluster copy number by tandem amplifica-
tion and increased expression was also described to confer resist-
ance reversion36,37 but for the VVESwe-S and VVESwe-R nanopore
assembly data showed that the vanA cluster appears as a single
copy in the Inc18-plasmid.
In conclusion, an alternative promoter conveys vanHAX expres-
sion independent of the vanR activator and is thus not inducible by
vancomycin. In addition, increased plasmid copy numbers add to
the resistant phenotype.
The novel resistance phenotype posed a low fitness cost
and was replaced by a susceptible phenotype over time
Acquisition of vancomycin resistance has been described to reduce
the fitness of the resistant strain compared with its susceptible
competitor in the absence of selective pressure.25,38,39 The relative
fitness cost for the revertant VVESwe-R was low: 6% as measured
by growth rate measurements and 9% in 24 h head-to-head
competition experiments (Figure 3a). A comparable fitness cost of
4%–9% was previously described for strains possessing vanA-plas-
mids when compared with their plasmid-free counterpart.25,39
We further investigated the stability of the resistance pheno-
type under non-selective conditions where the vanA-plasmid
would not be selected for. Over a period of 5 days the ratio of resist-
ant colonies was reduced significantly to 50% (Figure 3b). Of note,
the colonies were smaller on the vancomycin-containing plates
compared with the plates without vancomycin after 24 h, and the
plates were therefore re-checked after 48 h.
After serial transfer over 5 days, single colonies (n = 100) were
collected and subjected to differential plating on BHI plates
without and with vancomycin 8 mg/L. However, all 100 colonies
were able to grow on vancomycin plates after 72 h, suggesting
80







































































































Figure 2. mRNA and gDNA levels of vanRS and vanHAX operons relative to the housekeeping gene gdh in BM4147, the susceptible (VVESwe-S) and
resistant (VVESwe-R) isogenic VVE isolates grown in BHI broth without antimicrobials or in BHI broth with vancomycin 8 mg/L until mid-log phase. (a)
Expression level as measured by RT-qPCR (t-test, two-tailed, PBM4147 vanRS < 0.0001, PBM4147 vanHAX < 0.0001, PVVESwe-R vanHAX = 0.141). (b) gDNA level as
measured by qPCR (t-test, two-tailed, PBM4147 versus VVESwe-R = 0.0026, PVVESwe-R versus VVESwe-S = 0.0030). Bars are averages with SEM of three biological
replicates including four technical repeats each.
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that even though the number of susceptible colonies read after
24 h had increased, these colonies had not lost vanHAX. Sanger
sequencing of the vanSH PCR product of ten selected serial trans-
ferred colonies showed that no genetic changes had occurred
compared with VVESwe-R. Illumina WGS analysis of two selected
serial transferred colonies confirmed this. The vancomycin MIC
of the ten selected serial transferred colonies ranged from
32–64 mg/L (Figure 3c).
The copy number of vanHAX under non-selective conditions
was significantly reduced in serial transferred VVESwe-R compared
with non-serial transferred VVESwe-R and at a similar level to the
original VVESwe-S strain (Figure 3d). Thereby, the vanHAX-plasmid
copy number combined with the promoter region deletion are like-
ly responsible for the resistant phenotype and MIC variation of
VVESwe-R. We hypothesize that this decrease of vanHAX-copy
number also reduces the fitness cost of resistance and is therefore
evolutionarily advantageous. Further experimental studies are
needed to elucidate the mechanism of plasmid copy number
regulation.
In summary, we describe a VVE strain that can convert from a
vancomycin-susceptible to a vancomycin-resistant phenotype
and further to reduced resistance in response to differential vanco-
mycin exposure. During vancomycin exposure the parental
VVESwe-S strain converts to a VVESwe-R by a 44 bp deletion in the
vanHAX-promoter region and an increased vanA-plasmid copy
number (Figures 1 and 2). In the absence of vancomycin, the
VVESwe-R population acquired a phenotype of a lower vancomycin
MIC, which correlated to a decrease in vanA-plasmid copy number
(Figure 3d).
In line with previous publications,5,6 we observed the ability of
VVE to convert to a resistant phenotype during vancomycin selec-
tion. In a patient with a susceptible VVE infection, vancomycin
would provide the selective pressure needed for selection and
amplification of a resistant phenotype. Vancomycin is therefore
not a treatment option for VVE. Years after the discovery of VVEs, a
regional spread of VVE in Canada7 and a national spread of VVE in
Denmark was reported,9 which highlights the importance of
characterizing VVE clones and screening for their presence.
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Figure 3. Fitness and stability of the resistant revertant. (a) Relative fitness as assessed by growth rate and in head-to-head competition of VVESwe-
S and VVESwe-R. Bars show mean with SEM of three biological replicates in three technical repeats each (t-test, two-tailed; ns, P = 0.1746;
*P = 0.0134). (b) Stability of the VVESwe-R by serial transfer over 5 days. The plot shows mean with SEM of five biological replicates in three technical
repeats each (t-test, two-tailed, ***P < 0.0001). (c) Vancomycin MIC (mg/L) of serial transferred VVESwe-R-colonies compared with VVESwe-R
and VVESwe-S as measured with a MIC test strip. (d) Copy number of vanHAX normalized to gdh in VVESwe-R, VVESwe-S and serial transferred
VVESwe-R-colonies measured by qPCR on gDNA isolated from the strains grown in BHI broth without vancomycin until mid-log phase. Bars show
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